Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral
Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.
ALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.
Read MoreU.S. infant bleeding episodes rise as vitamin K shot refusals grow; rate fell from 97.7% to 95% (2017-2025) amid declining trust.
Read MoreFDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.
Read MoreFDA grants accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.
Read MoreThe FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.
Read MoreThe U.S. HHS awarded $247.9 million in grants to expand mental health and addiction treatment services nationwide.
Read MoreA Doctors Without Borders worker infected with Bundibugyo virus during DRC Ebola outbreak was evacuated to the Netherlands for specialized treatment.
Read MoreThe FDA authorized emergency use of Capstar and generic Nitenpyram to prevent and treat New World screwworm in dogs and cats nationwide.
Read MoreThe FDA approved Zanvastro, the first drug to treat Alexander disease by targeting abnormal GFAP buildup in pediatric and adult patients.
Read MoreCDC and state officials investigated a 2013 multistate Listeria outbreak linked to Crave Brothers soft-ripened cheeses sold at Whole Foods, leading to a recall.
Read More